BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Sunday, June 29, 2025
Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
Immuno-oncology RSS Feed RSS

Art concept for oncolytic virus
Immuno-oncology

IL-27-armed oncolytic virus cures pancreatic tumors, promoting long-term antitumor immunity in mice

May 15, 2025
No Comments
Pancreatic cancer is one of the deadliest malignancies, with a 5-year overall survival rate of only 13%. Earlier studies demonstrated that the Lister strain of oncolytic vaccinia virus (VVL) is capable of replicating and delivering therapeutic genes even under hypoxic conditions, highlighting its potential as a promising vector for targeting hypoxic tumors like pancreatic cancer.
Read More
Antibodies attacking cancer cell
Immuno-oncology

New anti-CCR8 immuno-oncology antibodies with unique binding/pharmacology

May 15, 2025
No Comments
CCR8 is highly expressed on immunosuppressive regulatory T cells (Tregs) in various solid tumors, making it a potential target to enhance antitumor immunity and the efficacy of cancer therapies, including checkpoint inhibitors. However, the impact of CCR8 expression on the Treg phenotype and its role in cancer progression remain unclear.
Read More
3D illustration of cancer in crosshairs
Immuno-oncology

Integrating antibody therapy and oncolytic virotherapy enhances effects

May 14, 2025
No Comments
Current anticancer approaches, such as antibody or CAR T-cell therapies, rely on targeting tumor-associated antigens rather than tumor-specific antigens, with the consequent on-target, off-tumor effects.
Read More
Immuno-oncology

HDAC6 inhibitor ITF-3756 targets multiple immune checkpoints

May 14, 2025
No Comments
Tumor immunotherapy has become a standard of care for treating various cancers, with immune checkpoint inhibitors targeting the PD-L1/PD-1 axis proving particularly effective. While PD-L1 expression on tumor cells is a predictive biomarker for therapeutic response, emerging evidence highlights the importance of PD-L1 expression on myeloid cells, such as monocytes and dendritic cells (DCs), in shaping the tumor microenvironment and influencing the success of checkpoint blockade.
Read More
CAR T-cell therapy in acute lymphoblastic leukemia
Immuno-oncology

Third-generation K12 CAR T shows strong activity in CD7+ T-cell malignancies and relapsed AML

May 13, 2025
No Comments
A study has demonstrated the potential of a novel ligand-based CAR T-cell therapy for targeting CD7-positive T-cell malignancies, including T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphomas. The receptor CD7 is a prominent target antigen, being expressed in around 95% of T-ALL, 50% of peripheral T-cell lymphomas and 10% of acute myeloid leukemias.
Read More
Cancer

New 5T4-targeted radiopharmaceutical shows single-dose efficacy in preclinical cancer models

May 13, 2025
No Comments
Radiopharmaceuticals can offer a targeted approach for cancers that have limited therapeutical options. Abdera Therapeutics Inc. recently presented results of their novel 5T4-targeted radiopharmaceutical.
Read More
Immuno-oncology

BB-1705 optimizes profile of EGFR-targeting therapies

May 13, 2025
No Comments
Epidermal growth factor receptor (EGFR), when overactive or overexpressed, may lead to tumor growth and spread, and is thus a robust target for therapy.
Read More
Digital cancer cells illustration
Immuno-oncology

Integrating AI-based neoantigen prediction and APC-targeted delivery to enhance cancer immunotherapy

May 12, 2025
No Comments
Traditional neoantigen prediction methods primarily rely on HLA-peptide binding databases, often producing false positives. This challenge highlights the need for improved strategies to identify truly immunogenic neoantigens. Neoantigen-based cancer vaccines have shown promising efficacy in recent clinical trials for treating solid tumors, offering a potential solution.
Read More
Immune checkpoint inhibitors illustration of PD-1, CTLA-4 and PD-L1.
Immuno-oncology

KGX-103 exerts antitumoral activity in vivo in A375 melanoma model

May 12, 2025
No Comments
Both IL-15 and IL-2 are good options for cancer therapy, but IL-15 is considered superior due to lower vascular endothelial toxicity, stronger ability to expand natural killer and CD8+ T cells and weaker stimulation of T regulatory cells, but it has a short half-life and exerts severe adverse effects.
Read More
Acute myeloid leukemia illustration
Immuno-oncology

The humanized antibody hu128.1 targeting TfR1 shows preclinical potential for erythroleukemia

May 12, 2025
No Comments
A recent study explored the therapeutic potential of hu128.1, a humanized antibody targeting transferrin receptor 1 (TfR1), in treating erythroleukemia using xenograft mouse models. The results demonstrate that hu128.1 exerts strong antitumor activity against human erythroleukemic (ERY-1) cells, highlighting its promise as a candidate for managing this aggressive cancer.
Read More
Previous 1 2 3 4 5 6 7 8 9 … 969 970 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 27, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 27, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 24, 2025
  • BIO2025: John Crowley and Martin Makary

    BIO 2025: Makary lays out FDA’s path, launches pilot review program

    BioWorld
    On the same day that FDA Commissioner Martin Makary spoke in a fireside chat during the 2025 Biotechnology Innovation Organization’s International Convention, the...
  • Andembry

    New orphan drug, CSL’s garadacimab, cleared for hereditary angioedema

    BioWorld
    Following a complete response letter issued last October over CMC issues, CSL Behring LLC gained U.S. FDA approval June 16 of its humanized anti-factor XIIa...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing